GlassScriptPhysician profile
Denise M Ware
NPI 1902167216
$6,339.91
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,598 · 2022: $2,861 · 2023: $1,694 · 2024: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,479.76 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $712.58 | 2021-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $650.23 | 2021-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $341.48 | 2021-2024 | Dificid |
| Janssen Biotech, INC. | $330.49 | 2022-2023 | Stelara, Simponi, Remicade |
| Intercept Pharmaceuticals, INC. | $324.86 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $210.70 | 2021-2023 | |
| Evoke Pharma, INC. | $191.48 | 2021-2023 | Gimoti |
| Gilead Sciences, INC. | $173.19 | 2021-2024 | |
| Ardelyx, INC. | $149.40 | 2022-2023 | Ibsrela |
| Pfizer INC. | $144.79 | 2022-2024 | |
| Qol Medical, LLC | $127.99 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $125.05 | 2021-2023 | Linzess |
| Genzyme Corporation | $98.78 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $51.00 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.65 | 2022-2023 | Dupixent |
| Acadia Pharmaceuticals INC | $43.57 | 2024 | Nuplazid |
| Celgene Corporation | $37.19 | 2021-2022 | |
| Alfasigma USA, INC. | $28.16 | 2021 | |
| Novo Nordisk INC | $17.68 | 2023 | Wegovy |
| Alnylam Pharmaceuticals INC. | $15.55 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.84 | 2021 | |
| Boston Scientific Corporation | $13.00 | 2022 | |
| Daiichi Sankyo INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.